Acadia Extends Allergan Pact a Year

Xconomy San Diego — 

San Diego-based Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), which specializes in developing novel biopharmaceuticals for central nervous system disorders, has extended a collaboration agreement with Irvine, CA-based Allergan (NYSE: AGN) to develop new therapeutics for glaucoma and other disorders. Acadia says the drug development partnership established in 2003 was extended through next March. Acadia has two other collaboration agreements with Allergan, with clinical programs in development for glaucoma and chronic pain.